CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia/MDS test shows an IDH1 change called R132 (other IDH1 changes may be possible only after discussion with the study doctor).
- You have AML that is new or has returned/resisted treatment, or you have high-risk MDS; you must be eligible for intensive chemotherapy (or the MDS/high-risk type may also qualify after review).
- Your day-to-day functioning is good enough (ECOG 0 to 2).
- Your liver and kidney blood tests are within safe ranges (bilirubin not too high; ALT/AST not too high; kidney filtration rate at least 30 mL/min).
- You must not have already received CPX-351, and you can sign informed consent.
- You must be able to take the study medicines by mouth as instructed (no major stomach/intestine or body-milk/chemical problems that would block absorption).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.